Is Anything Else Is Impacting Valeant Besides Brexit?

The video discusses the impact of Brexit on the biopharmaceutical industry, highlighting Valeant's financial struggles due to its significant debt and sensitivity to market turmoil. While some European pharmaceutical companies may benefit from Brexit, Valeant faces unique risks. The video also covers the potential challenges to the Anthem-Cigna merger, with regulatory scrutiny from the Justice Department being a key concern.

How has Brexit impacted the biopharmaceutical industry according to the text?

What challenges is Valeant facing in relation to its debt?

What was the perspective of the European equity strategist regarding the pharmaceutical sector in Europe?

What are the potential risks for Valeant compared to other companies in the pharmaceutical sector?

What is the current status of the Anthem and Cigna merger according to the text?